tiprankstipranks
AIM ImmunoTech Executives Forego Bonuses for R&D Focus
Company Announcements

AIM ImmunoTech Executives Forego Bonuses for R&D Focus

Story Highlights

Don't Miss Our Christmas Offers:

An announcement from AIM ImmunoTech ( (AIM) ) is now available.

AIM ImmunoTech announced that Thomas K. Equels and Peter W. Rodino III have decided to forego their entitled cash bonuses for 2024. This decision aims to allocate more financial resources towards the company’s Ampligen research and development activities, reflecting a strategic move to prioritize long-term growth and innovation over immediate compensation.

More about AIM ImmunoTech

YTD Price Performance: -56.72%

Average Trading Volume: 448,657

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $12.12M

Find detailed analytics on AIM stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyAIM ImmunoTech receives noncompliance notification from NYSE
TheFlyAIM ImmunoTech expands patent portfolio with new Netherlands patent
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App